|
- NuProbe | Improving analytical sensitivity in DNA biomarkers
At NuProbe, we are developing innovative assays to accelerate cancer research Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens
- About NuProbe | Improving analytical sensitivity in DNA biomarkers
Using proprietary technologies, NuProbe develops and validates research panels to address unmet needs for detecting and monitoring low-frequency mutations, gene fusions, and copy number alterations (CNAs) Founded in 2016, NuProbe is a privately held company with facilities in Houston, TX and China
- BDA | qPCR NGS | NuProbe
The NuProbe team has pioneered the development of PCR-based enrichment method called Blocker Displacement Amplification (BDA)
- Ultrasensitive Detection for Liquid Biopsy . Solid Tumor . . . - NuProbe
NuProbe has used the Blocker Displacement Amplification (BDA) technology to create several proof of concept assays These assays demonstrate the capabilities and benefits of this technology, including its ability for more efficient use of sequencing capacity
- Careers at NuProbe
Working at NuProbe provides me the opportunity to collaborate not only with my fellow scientists from NuProbe, but also with those from institutions and organizations across the globe
- Contact us - NuProbe
© 2025 NuProbe All Rights Reserved This website uses cookies By continuing to use this site, you accept our use of cookies View our Privacy Policy
- News - Press Releases | NuProbe
Access news about breakthrough technologies in precision diagnostics and genomics led by the NuProbe team
- QASeq | ultrasensitive CNV detection via NGS | NuProbe
NuProbe’s Quantitative Amplicon Sequencing (QASeq) is an amplicon-based NGS method that enables accurate, highly multiplexed detection and quantitation of CNVs and mutations
|
|
|